Ulcerative Colitis

For Ulcerative Colitis, Two First-In-Class Candidates and an Interleukin-23 Competition

February 01, 2023

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.

Microscopic Intestinal Inflammation Linked to Increased Risk of Preterm Birth in Women with Ulcerative Colitis

January 23, 2023

Other adverse outcomes were not linked to histological inflammation, according to results of a Swedish study.

Up-and-Coming Treatments for Ulcerative Colitis Have Novel Mechanisms of Action

January 13, 2023

Cobitolimod from InDex, a Swedish company, and obefazimod, from Abivax, a French company, could be first-in-class medications for ulcerative colitis.

Engineered Probiotics Target Proinflammatory Molecules and Improve Ulcerative Colitis Symptoms

January 09, 2023

Stomach acid interferes with the effectiveness of probiotics taken as pills. Researchers are bioengineering probiotics in hopes of getting around that problem.